BRCA mutations cause reduction in miR-200c expression in triple negative breast cancer

Gene

Volumn 556, Issue 2, 2015, Pages 163-169

  Erturk, Elif ^a   Cecener, Gulsah ^a   Tezcan, Gulcin ^a   Egeli, Unal ^a   Tunca, Berrin ^a   Gokgoz, Sehsuvar ^a   Tolunay, Sahsine ^a   Tasdelen, Ismet ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

BRCA1 2 gene mutations; MicroRNA; MiR 200c; Triple negative breast cancer

Indexed keywords

MICRORNA 200C; BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN; MICRORNA; MIRN200 MICRORNA, HUMAN; MIRNLET7 MICRORNA, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; HUMAN TISSUE; LET 7A GENE; ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR INVASION; VEGFA GENE; DISEASE COURSE; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY;

ADULT; BRCA1 PROTEIN; BRCA2 PROTEIN; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MIDDLE AGED; MUTATION; TRIPLE NEGATIVE BREAST NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84919872180     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2014.11.047     Document Type: Article

References (71)

1. Abeliovich D., et al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am. J. Hum. Genet. 1997, 60:505-514.
2. Adam L., et al. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin. Cancer Res. 2009, 15:5060-5072.
3. Baffa R., et al. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J. Pathol. 2009, 219:214-221.
4. Bertheau P., et al. Exquisite sensitivity of Tp53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med. 2007, 4:90-95.
5. Blick T., Hugo H. Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer. J. Mammary Gland Biol. Neoplasia 2010, 15:235-252.
6. Boominathan L. The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNAs network. Cancer Metastasis Rev. 2010, 4:613-639.
7. Brewster B.L., et al. Identification of fifteen novel germline variants in the BRCA1 3'UTR reveals a variant in a breast cancer case that introduces a functional miR-103 target site. Hum. Mutat. 2012, 33:1665-1675.
8. Buffa F.M., Camps C. MicroRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res. 2011, 71:5635-5645.
9. Burk U., Schubert J. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008, 9:582-589.
10. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6:857-866.
11. Carey L.A., et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 2007, 13:2329-2334.
12. Cascione L., et al. Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. PLoS One 2013, 8(2):e55910. 10.1371/journal.pone.0055910.
13. Castilla M.Á., Díaz-Martín J. MicroRNA-200 family modulation in distinct breast cancer phenotypes. PLoS One 2012, 7(10):e47709. 10.1371/journal.pone.0047709.
14. Cecener G., et al. BRCA1/2 germline mutations and their clinical importance in Turkish breast cancer patients. Cancer Investig. 2014, 1-13. 10.3109/07357907.2014.919302.
15. Chang C.J., et al. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat. Cell Biol. 2011, 3:317-323.
16. Chang B.P., et al. miR-200c inhibits metastasis of breast cancer cells by targeting HMGB1. J. Huazhong Univ. Sci. Technol. Med. Sci. 2014, 34:201-206.
17. Chen J., Tian W. Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer. Med. Oncol. 2012, 29:2527-2534.
18. Chuang T.D., et al. miR-200c is aberrantly expressed in leiomyomas in an ethnic-dependent manner and targets ZEBs, VEGFA, TIMP2, and FBLN5. Endocr. Relat. Cancer 2012, 19:541-556.
19. Cochrane D.R., et al. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol. Cancer Ther. 2009, 5:1055-1066.
20. Cui J., et al. Downregulation of miR-200c promotes radiation-induced thymic lymphoma by targeting BMI1. J. Cell. Biochem. 2014, 6:1033-1042.
21. D'Ippolito E., Iorio M.V. MicroRNAs and triple negative breast cancer. Int. J. Mol. Sci. 2013, 14:22202-22220.
22. Egeli U., et al. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives. Cancer Investig. 2006, 24:484-491.
23. Erturk E., et al. Expression status of let-7a and miR-335 among breast tumors in patients with and without germ-line BRCA mutations. Mol. Cell. Biochem. 2014, 10.1007/s11010-014-2113-4.
24. Ferla R., Cal'o V. Founder mutations in BRCA1 and BRCA2 genes. Ann. Oncol. 2007, 6:93-98.
25. Fish J.E., et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev. Cell 2008, 15:272-2784.
26. Foulkes W.D., et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res. 2004, 64:830-835.
27. Greenup R., et al. Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Ann. Surg. Oncol. 2013, 20:3254-3258.
28. Gregory P.A., et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 2008, 10:593-601.
29. Haffty B.G., et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J. Clin. Oncol. 2006, 24:5652-5657.
30. Howe E.N., et al. Targets of miR-200c mediate suppression of cell motility and anoikis resistance. Breast Cancer Res. 2011, 13(2):R45. 10.1186/bcr2867.
31. Howe E.N., et al. miR-200c targets a NF-kB up-regulated TrkB/NTF3 autocrine signaling loop to enhance anoikis sensitivity in triple negative breast cancer. PLoS One 2012, 7(11):e49987. 10.1371/journal.pone.0049987.
32. Huang H.N., et al. miR-200c and GATA binding protein 4 regulate human embryonic stem cell renewal and differentiation. Stem Cell Res. 2014, 2:338-353.
33. Hur K., et al. MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut 2013, 62:1315-1326.
34. Hurteau G.J., et al. Stable expression of miR-200c alone is sufficient to regulate TCF8 (ZEB1) and restore E-cadherin expression. Cell Cycle 2009, 8:2064-2069.
35. Iorio M.V., et al. MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer. Eur. J. Cancer 2008, 44:2753-2759.
36. Janssen E.A., et al. Biologic profiling of lymph node negative breast cancers by means of microRNA expression. Mod. Pathol. 2010, 23:1567-1576.
37. Johnson C.D., et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res. 2007, 67:7713-7722.
38. Jurmeister S., et al. MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F. Mol. Cell. Biol. 2012, 32:633-651.
39. Katoh Y., Katoh M. Hedgehog signaling, epithelial-to-mesenchymal transition and miRNA (review). Int. J. Mol. Med. 2008, 22:271-275.
40. Kim S.J., et al. MicroRNA let-7a suppresses breast cancer cell migration and invasion through downregulation of CC chemokine receptor type 7. Breast Cancer Res. 2012, 18:14-26.
41. Kontorovich T., et al. Single nucleotide polymorphisms in miRNA binding sites and miRNA genes as breast/ovarian cancer risk modifiers in Jewish high-risk women. Int. J. Cancer 2010, 127:589-597.
42. Kopp F., Wagner E., Roidl A. The proto-oncogene KRAS is targeted by miR-200c. Oncotarget 2014, 5:185-195.
43. Korpal M., Lee E.S. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J. Biol. Chem. 2008, 283:14910-14914.
44. Lehmann B.D., Bauer J.A. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 2011, 121:2750-2767.
45. Lheureux S., et al. Two novel variants in the 3'UTR of the BRCA1 gene in familial breast and/or ovarian cancer. Breast Cancer Res. Treat. 2011, 125:885-891.
46. Liao C., et al. MicroRNA-200c inhibits apoptosis in pituitary adenoma cells by targeting the PTEN/Akt signaling pathway. Oncol. Res. 2014, 21:129-136.
47. Lin J., Liu C. miR-200c enhances radiosensitivity of human breast cancer cells. J. Cell. Biochem. 2013, 114:606-615.
48. Liu H., et al. Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell renal cell carcinoma. BMC Syst. Biol. 2010, 4:51. 10.1186/1752-0509-4-51.
49. Liu S., Tetzlaff M.T., Cui R., Xu X. miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1. Am. J. Pathol. 2012, 181:1823-1835.
50. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-C(T)) method. Methods 2001, 25:402-408.
51. Lu Y.X., et al. Regulation of colorectal carcinoma stemness, growth, and metastasis by an miR-200c-Sox2-negative feedback loop mechanism. Clin. Cancer Res. 2014, 20:2631-2642.
52. Luna C., et al. Regulation of trabecular meshwork cell contraction and intraocular pressure by miR-200c. PLoS One 2012, 7(12):e51688. 10.1371/journal.pone.0051688.
53. Negrini M., et al. MicroRNAs in human cancer: from research to therapy. J. Cell Sci. 2007, 120:1833-1840.
54. Neves R., et al. Role of DNA methylation in miR-200c/141 cluster silencing in invasive breast cancer cells. BMC Res. Notes 2010, 3:3-7.
55. Ota T., et al. KRAS up-regulates the expression of miR-181a, miR-200c and miR-210 in a three-dimensional-specific manner in DLD-1 colorectal cancer cells. Anticancer Res. 2012, 32:2271-2275.
56. Panda H., Pelakh L., Chuang T.D., Luo X., Bukulmez O., Chegini N. Endometrial miR-200c is altered during transformation into cancerous states and targets the expression of ZEBs, VEGFA, FLT1, IKKβ, KLF9, and FBLN5. Reprod. Sci. 2012, 8:786-796.
57. Radojicic J., et al. MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle 2011, 10:507-517.
58. Sempere L.F., et al. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res. 2007, 67:11612-11620.
59. Sorlie T., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. 2001, 98:10869-10874.
60. Sorlie T., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. 2003, 100:8418-8423.
61. Stinson S., et al. TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer. Sci. Signal. 2011, 4:14-25.
62. Takamizawa J., et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004, 64:3753-3756.
63. Tao T., et al. Autoregulatory feedback loop of EZH2/miR-200c/E2F3 as a driving force for prostate cancer development. Biochim. Biophys. Acta 2014, (pii: S1874-9399(14)00189-8, Epub ahead of print). 10.1016/j.bbagrm.2014.07.001.
64. Tryndyak V.P., Beland F.A., Pogribny I.P. E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int. J. Cancer 2010, 126:2575-2583.
65. Vaksman O., et al. miRNA profiling along tumour progression in ovarian carcinoma. J. Cell. Mol. Med. 2011, 15:1593-1602.
66. Van 't Veer L.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
67. Volinia S., et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. 2006, 103:2257-2261.
68. Wang J., Zhao H. Overexpressions of MicroRNA-9 and MicroRNA-200c in human breast cancers are associated with lymph node metastasis. Cancer Biother. Radiopharm. 2013, 28:283-288.
69. Wang S., et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev. Cell 2008, 15:261-271.
70. Zhang H., et al. The microRNA network and tumor metastasis. Oncogene 2010, 29:937-948.
71. Zhao Y., et al. let-7 microRNAs induce tamoxifen sensitivity by downregulation of estrogen receptor alpha signaling in breast cancer. Mol. Med. 2011, 17:1233-1241.